Prevalence and outcomes of primary bedaquiline resistance in adults with rifampicin-resistant pulmonary tuberculosis

Clicks: 3
ID: 338891
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #323 of 324 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 324 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Bedaquiline resistance (BDQ-R) is increasing worldwide, but the contribution of primary BDQ-R remains unclear in countries with a high burden of RR-TB and widespread bedaquiline use. We aimed to estimate the prevalence of primary BDQ-R and to describe treatment outcomes amongst adults with primary BDQ-R in the Western Cape province, South Africa. Methods We conducted a retrospective cohort study of patients with BDQ-R identified through routine phenotypic bedaquiline susceptibility testing. Among patients with baseline BDQ-R (defined as resistance detected in those on no RR-TB treatment or with <1 month of treatment exposure), BDQ-R was categorised as primary (no prior bedaquiline exposure) or acquired (prior bedaquiline exposure). Drug resistance profiles, treatment outcomes, and time to culture conversion were analysed. Results Among 146 patients with baseline BDQ-R, 81 (55%) had primary BDQ-R. Resistance to other RR-TB drugs was common (except for linezolid). Of 80 patients with baseline BDQ-R and a treatment outcome, 28 (35%) died at a median of 276 days (IQR 129–459) after BDQ-R diagnosis. 117/136 (86%) achieved sputum culture conversion in a median of 97 days (IQR 89 –116). Acquired BDQ-R was associated with a lower hazard of culture conversion (adjusted HR: 0.37; p<0.001) and fewer favourable treatment outcomes (12.5% vs 47.9%; P=0.001) than primary BDQ-R. Conclusion Over half of BDQ-R cases were due to primary transmission. Outcomes were poor, but better in primary than acquired BDQ-R. Optimized susceptibility testing and treatment strategies are urgently needed to limit BDQ-R transmission.
Reference Key
openalex_W7225340252 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Peter G. Beckwith, James C.M. Brust, Graeme Meintjes, Shaheed Vally Omar, Julian te Riele, Norbert O. Ndjeka, Gary Maartens
Are you one of these authors? Claim your profile
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag715
URL
https://doi.org/10.1093/ofid/ofag715
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.